Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) Meeting Abstract
| Authors: | Motzer, R. J.; Porta, C.; Eto, M.; Powles, T.; Grünwald, V.; Hutson, T. E.; Alekseev, B.; Rha, S. Y.; Merchan, J. R.; Goh, J. C.; Kapoor, A.; De Giorgi, U.; Melichar, B.; Hong, S. H.; Gurney, H.; Rodriguez-Lopez, K.; He, C. S.; Okpara, C.; McKenzie, J.; Choueiri, T. K. |
| Abstract Title: | Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.4502 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 4502 -- This meeting was also held virtually -- Source: Cinahl |
